OncoMatch/Clinical Trials/NCT04641247
A Long-term Treatment Extension Study of Niraparib in Participants Who Completed a Prior GlaxoSmithKline/TESARO-sponsored Niraparib Study
Is NCT04641247 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Niraparib for ovarian neoplasms.
Treatment: Niraparib — This is a global extension study to provide continued access to niraparib and further characterize the long-term safety of niraparib treatment in participants who are currently receiving treatment with niraparib within GlaxoSmithKline/TESARO-sponsored studies (NCT01847274, NCT02354586, NCT01905592, NCT03308942, NCT02657889) that has fulfilled the requirements for the primary objective.
Check if I qualifyExtracted eligibility criteria
Cancer type
Ovarian Cancer
Breast Carcinoma
Prior therapy
Must have received: PARP inhibitor (niraparib) — parent GlaxoSmithKline/TESARO-sponsored study
currently receiving treatment with niraparib (as monotherapy or in combination) in a GlaxoSmithKline/TESARO-sponsored study that has fulfilled the requirements for the primary objective
Cannot have received: PARP inhibitor (niraparib)
has been permanently discontinued from niraparib treatment in the parent study for any reason
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- GSK Investigational Site · Tucson, Arizona
- GSK Investigational Site · Encinitas, California
- GSK Investigational Site · Los Angeles, California
- GSK Investigational Site · Whittier, California
- GSK Investigational Site · Jacksonville, Florida
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify